Kezar Life Sciences (KZR)
(Real Time Quote from BATS)
$0.67 USD
-0.01 (-1.83%)
Updated Jun 17, 2024 11:22 AM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Kezar Life Sciences, Inc. [KZR]
Reports for Purchase
Showing records 21 - 35 ( 35 total )
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
KZR-261 Phase 1 Patient Dosing Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
KZR-616 MISSION Data in 4Q21; PRESIDIO Trial Fully Enrolled; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
KZR-616 Clinical Readouts Approaching; 1Q21 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
KZR-616 Progress; KZR-261 Clinical Entry Nears; 2020 Financials; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
KZR-261 Entering Clinic Next Year; 3Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
KZR-616 Orphan Status in Dermatomyositis and Polymyositis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
MISSION Phase 1b Data From First Five Cohorts Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Progress Continues; 2Q20 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
KZR-616 Interim MISSION Data Encouraging; Raising PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
KZR-616 Interim Data Imminent; 1Q20 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
Model Updates; Clinical Trials Paused; Lowering PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
KZR-616 Continues to Progress; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 Financial Results Reported; Spending In-Line; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Kezar Life Sciences, Inc.
Industry: Medical - Biomedical and Genetics
On the Cusp of a Comeback; Initiating at Buy and $15 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R